Radium-223 mechanism of action: implications for use in treatment combinations

Michael J. Morris, Eva Corey, Theresa A. Guise, James L. Gulley, William Kevin Kelly, David I. Quinn, Arne Scholz, George Sgouros

Research output: Contribution to journalReview article

Abstract

The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known visceral metastases. Preclinical studies demonstrate that 223Ra preferentially incorporates into newly formed bone matrix within osteoblastic metastatic lesions. The emitted high-energy alpha particles induce DNA double-strand breaks that might be irreparable and lead to cell death in nearby exposed tumour cells, osteoblasts and osteoclasts. Consequently, tumour growth and abnormal bone formation are inhibited by these direct effects and by the disruption of positive-feedback loops between tumour cells and the bone microenvironment. 223Ra might also modulate immune responses within the bone. The clinical utility of 223Ra has encouraged the development of other anticancer targeted alpha therapies. A thorough understanding of the mechanism of action could inform the design of new combinatorial treatment strategies that might be more efficacious than monotherapy. On the basis of the current mechanistic knowledge and potential clinical benefits, combination therapies of 223Ra with microtubule-stabilizing cytotoxic drugs and agents targeting the androgen receptor axis, immune checkpoint receptors or DNA damage response proteins are being explored in patients with CRPC and metastatic bone disease.

Original languageEnglish (US)
Pages (from-to)745-756
Number of pages12
JournalNature Reviews Urology
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2019

Fingerprint

Radium
Castration
Bone and Bones
Prostatic Neoplasms
Alpha Particles
Neoplasm Metastasis
Cellular Microenvironment
Bone Neoplasms
Neoplasms
Bone Matrix
Double-Stranded DNA Breaks
Bone Diseases
Cytotoxins
Androgen Receptors
Osteoclasts
Therapeutics
Drug Delivery Systems
Osteoblasts
Osteogenesis
Microtubules

ASJC Scopus subject areas

  • Urology

Cite this

Morris, M. J., Corey, E., Guise, T. A., Gulley, J. L., Kevin Kelly, W., Quinn, D. I., ... Sgouros, G. (2019). Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology, 16(12), 745-756. https://doi.org/10.1038/s41585-019-0251-x

Radium-223 mechanism of action : implications for use in treatment combinations. / Morris, Michael J.; Corey, Eva; Guise, Theresa A.; Gulley, James L.; Kevin Kelly, William; Quinn, David I.; Scholz, Arne; Sgouros, George.

In: Nature Reviews Urology, Vol. 16, No. 12, 01.12.2019, p. 745-756.

Research output: Contribution to journalReview article

Morris, MJ, Corey, E, Guise, TA, Gulley, JL, Kevin Kelly, W, Quinn, DI, Scholz, A & Sgouros, G 2019, 'Radium-223 mechanism of action: implications for use in treatment combinations', Nature Reviews Urology, vol. 16, no. 12, pp. 745-756. https://doi.org/10.1038/s41585-019-0251-x
Morris, Michael J. ; Corey, Eva ; Guise, Theresa A. ; Gulley, James L. ; Kevin Kelly, William ; Quinn, David I. ; Scholz, Arne ; Sgouros, George. / Radium-223 mechanism of action : implications for use in treatment combinations. In: Nature Reviews Urology. 2019 ; Vol. 16, No. 12. pp. 745-756.
@article{1cffd10d91c34f13aa78d5939522265b,
title = "Radium-223 mechanism of action: implications for use in treatment combinations",
abstract = "The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known visceral metastases. Preclinical studies demonstrate that 223Ra preferentially incorporates into newly formed bone matrix within osteoblastic metastatic lesions. The emitted high-energy alpha particles induce DNA double-strand breaks that might be irreparable and lead to cell death in nearby exposed tumour cells, osteoblasts and osteoclasts. Consequently, tumour growth and abnormal bone formation are inhibited by these direct effects and by the disruption of positive-feedback loops between tumour cells and the bone microenvironment. 223Ra might also modulate immune responses within the bone. The clinical utility of 223Ra has encouraged the development of other anticancer targeted alpha therapies. A thorough understanding of the mechanism of action could inform the design of new combinatorial treatment strategies that might be more efficacious than monotherapy. On the basis of the current mechanistic knowledge and potential clinical benefits, combination therapies of 223Ra with microtubule-stabilizing cytotoxic drugs and agents targeting the androgen receptor axis, immune checkpoint receptors or DNA damage response proteins are being explored in patients with CRPC and metastatic bone disease.",
author = "Morris, {Michael J.} and Eva Corey and Guise, {Theresa A.} and Gulley, {James L.} and {Kevin Kelly}, William and Quinn, {David I.} and Arne Scholz and George Sgouros",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41585-019-0251-x",
language = "English (US)",
volume = "16",
pages = "745--756",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Radium-223 mechanism of action

T2 - implications for use in treatment combinations

AU - Morris, Michael J.

AU - Corey, Eva

AU - Guise, Theresa A.

AU - Gulley, James L.

AU - Kevin Kelly, William

AU - Quinn, David I.

AU - Scholz, Arne

AU - Sgouros, George

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known visceral metastases. Preclinical studies demonstrate that 223Ra preferentially incorporates into newly formed bone matrix within osteoblastic metastatic lesions. The emitted high-energy alpha particles induce DNA double-strand breaks that might be irreparable and lead to cell death in nearby exposed tumour cells, osteoblasts and osteoclasts. Consequently, tumour growth and abnormal bone formation are inhibited by these direct effects and by the disruption of positive-feedback loops between tumour cells and the bone microenvironment. 223Ra might also modulate immune responses within the bone. The clinical utility of 223Ra has encouraged the development of other anticancer targeted alpha therapies. A thorough understanding of the mechanism of action could inform the design of new combinatorial treatment strategies that might be more efficacious than monotherapy. On the basis of the current mechanistic knowledge and potential clinical benefits, combination therapies of 223Ra with microtubule-stabilizing cytotoxic drugs and agents targeting the androgen receptor axis, immune checkpoint receptors or DNA damage response proteins are being explored in patients with CRPC and metastatic bone disease.

AB - The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known visceral metastases. Preclinical studies demonstrate that 223Ra preferentially incorporates into newly formed bone matrix within osteoblastic metastatic lesions. The emitted high-energy alpha particles induce DNA double-strand breaks that might be irreparable and lead to cell death in nearby exposed tumour cells, osteoblasts and osteoclasts. Consequently, tumour growth and abnormal bone formation are inhibited by these direct effects and by the disruption of positive-feedback loops between tumour cells and the bone microenvironment. 223Ra might also modulate immune responses within the bone. The clinical utility of 223Ra has encouraged the development of other anticancer targeted alpha therapies. A thorough understanding of the mechanism of action could inform the design of new combinatorial treatment strategies that might be more efficacious than monotherapy. On the basis of the current mechanistic knowledge and potential clinical benefits, combination therapies of 223Ra with microtubule-stabilizing cytotoxic drugs and agents targeting the androgen receptor axis, immune checkpoint receptors or DNA damage response proteins are being explored in patients with CRPC and metastatic bone disease.

UR - http://www.scopus.com/inward/record.url?scp=85075179257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075179257&partnerID=8YFLogxK

U2 - 10.1038/s41585-019-0251-x

DO - 10.1038/s41585-019-0251-x

M3 - Review article

C2 - 31712765

AN - SCOPUS:85075179257

VL - 16

SP - 745

EP - 756

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 12

ER -